FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 171 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 12.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $28,000 | -54.8% | 4,651 | 0.0% | 0.00% | – |
| Q1 2019 | $62,000 | +47.6% | 4,651 | 0.0% | 0.00% | – |
| Q4 2018 | $42,000 | -35.4% | 4,651 | 0.0% | 0.00% | – |
| Q3 2018 | $65,000 | -11.0% | 4,651 | 0.0% | 0.00% | – |
| Q2 2018 | $73,000 | -8.8% | 4,651 | 0.0% | 0.00% | – |
| Q1 2018 | $80,000 | -21.6% | 4,651 | 0.0% | 0.00% | – |
| Q4 2017 | $102,000 | +12.1% | 4,651 | +98.3% | 0.00% | – |
| Q3 2017 | $91,000 | +28.2% | 2,346 | 0.0% | 0.00% | – |
| Q2 2017 | $71,000 | -16.5% | 2,346 | 0.0% | 0.00% | – |
| Q1 2017 | $85,000 | -28.0% | 2,346 | 0.0% | 0.00% | – |
| Q4 2016 | $118,000 | -52.0% | 2,346 | -50.0% | 0.00% | – |
| Q3 2016 | $246,000 | +153.6% | 4,692 | +100.0% | 0.00% | – |
| Q2 2016 | $97,000 | +2.1% | 2,346 | 0.0% | 0.00% | – |
| Q1 2016 | $95,000 | -2.1% | 2,346 | 0.0% | 0.00% | – |
| Q4 2015 | $97,000 | – | 2,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 115,500 | $2,531,000 | 0.89% |
| AWM Investment Company, Inc. | 150,000 | $3,288,000 | 0.64% |
| BB BIOTECH AG | 827,500 | $18,139,000 | 0.51% |
| Virtus ETF Advisers LLC | 17,371 | $381,000 | 0.48% |
| Rock Springs Capital Management LP | 425,000 | $9,316,000 | 0.42% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 450,728 | $9,880,000 | 0.39% |
| Telemetry Investments, L.L.C. | 44,176 | $968,000 | 0.37% |
| RTW INVESTMENTS, LP | 100,377 | $2,200,000 | 0.37% |
| Eventide Asset Management | 315,000 | $6,905,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 52,500 | $1,151,000 | 0.22% |